Relmada Therapeutics, Inc. (RLMD)

NASDAQ: RLMD · Real-Time Price · USD

0.2736

+0.0036 (1.33%)

At close: Apr 1, 2025, 4:00 PM

0.2856

+0.0120 (4.39%)

After-hours: Apr 1, 2025, 4:34 PM EDT

Relmada Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Selling, General & Admin	37.72	48.89	47.93	35.08	24.87	Upgrade
Research & Development	46.18	54.81	113.32	90.62	34.47	Upgrade
Operating Expenses	83.89	103.7	161.25	125.7	59.34	Upgrade
Operating Income	-83.89	-103.7	-161.25	-125.7	-59.34	Upgrade
Interest & Investment Income	3.53	5.15	2.66	1.2	1.4	Upgrade
EBT Excluding Unusual Items	-80.36	-98.55	-158.59	-124.5	-57.94	Upgrade
Gain (Loss) on Sale of Investments	0.38	-0.24	-4.81	-1.25	-0.02	Upgrade
Other Unusual Items	-	-	6.35	-	-1.5	Upgrade
Pretax Income	-79.98	-98.79	-157.04	-125.75	-59.46	Upgrade
Net Income	-79.98	-98.79	-157.04	-125.75	-59.46	Upgrade
Net Income to Common	-79.98	-98.79	-157.04	-125.75	-59.46	Upgrade
Shares Outstanding (Basic)	30	30	30	18	16	Upgrade
Shares Outstanding (Diluted)	30	30	30	18	16	Upgrade
Shares Change (YoY)	0.21%	1.59%	68.80%	12.56%	68.97%	Upgrade
EPS (Basic)	-2.65	-3.28	-5.30	-7.16	-3.81	Upgrade
EPS (Diluted)	-2.65	-3.28	-5.30	-7.16	-3.81	Upgrade
Free Cash Flow	-51.76	-51.66	-103.8	-91.87	-27.81	Upgrade
Free Cash Flow Per Share	-1.72	-1.72	-3.50	-5.23	-1.78	Upgrade
EBITDA	-	-	-161.25	-125.7	-59.33	Upgrade
D&A For EBITDA	-	-	0	0	0	Upgrade
EBIT	-83.89	-103.7	-161.25	-125.7	-59.34	Upgrade

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q